Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 22nd Century Group, Inc.XXII · Entity 8519 | VP of Plant Biotechnology | May 24, 2017 | May 26, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
22nd Century Group, Inc.
Report date May 24, 2017 · Filed May 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2027-05-24 | Direct | 58,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 58,000 · Balance 58,000 F1: Stock option grant which vests one-third on each of April 1, 2018, April 1, 2019 and April 1, 2020. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2026-03-04 | Direct | 79,787 |
Reported balance
Holding disclosure · report date 2017-05-24 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 79,787 F2: Stock option grant which vests one-third on each of March 4, 2017, March 4, 2018 and March 4, 2019. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2025-10-07 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-05-24 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option grant which vests one-third on each of April 1, 2018, April 1, 2019 and April 1, 2020.
F2: Stock option grant which vests one-third on each of March 4, 2017, March 4, 2018 and March 4, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2017 Filed May 26, 2017 20:26 UTC | 22nd Century Group, Inc. XXII · Entity 8519 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $1.39 Strike: $1.39 | $80,620.00 |
DisclosureSEC source: 0001140361-17-022556 · doc1.xml · derivative · entry 1 RUSHTON PAUL · CIK 0001655330 · VP of Plant Biotechnology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Stock option grant which vests one-third on each of April 1, 2018, April 1, 2019 and April 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.